DprE1-IN-2 is primarily used in research focused on developing new treatments for tuberculosis. It acts as an inhibitor of the DprE1 enzyme, which is essential for the biosynthesis of the bacterial cell wall in Mycobacterium tuberculosis. By targeting this enzyme, it disrupts the cell wall formation, leading to the death of the bacteria. This makes it a valuable compound in the study of potential antitubercular drugs, particularly in addressing drug-resistant strains of tuberculosis. Researchers utilize it to explore mechanisms of bacterial resistance and to design more effective therapeutic agents.